Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to follow the study procedures throughout the trial
- People who are between 50 and 80 years old at the time of signing the consent form
- People who have been clinically diagnosed with neovascular age-related macular degeneration (a specific type of eye condition affecting the retina)
- People who have active abnormal blood vessel growth in the eye related to their condition
- People whose vision in the study eye falls within a specific range on a standard eye test (between 24 and 73 letters on an eye chart)
Who may not be able to join:
- People who have any other eye condition in the study eye — apart from the macular degeneration being studied — that could affect vision improvement or that would need treatment during the trial, as determined by the investigating doctor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaorong Li, Professor, Tianjin Medical University Eye Hospital
Phone: 86-021-58206061
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability after FT-003 injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.